Program
enrupatinib
Also written as “EI-1071” and “EI-1071 tablet, oral”.
Its studies are mostly in Lymphoma, Follicular, led by Elixiron Immunotherapeutics.
Furthest: phase 2, since Dec 12, 20243 company-led studies, 1 open or runningNext primary completion: Aug 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Elixiron Immunotherapeutics | 31 open or running | phase 2since Dec 12, 2024 | Jan 16, 2020 | Aug 2027phase 1 · NCT07903337 |
Also a collaborator on its studies: parexel.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 16, 2020First study: phase 1 study in Healthy VolunteersFirst studyNCT04238364 · 58 enrolled · United States
- Dec 12, 2024Phase 2 study in Lymphoma, FollicularNCT06745583 · 7 enrolled · Taiwan
- Sep 29, 2026Phase 1 study in Food Effect in Healthy VolunteersNCT07903337 · 25 planned · Taiwan
Ahead
- Aug 2027Primary completion: phase 1 study in Food Effect in Healthy VolunteersNCT07903337
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07903337Food Effect in Healthy Volunteers · Taiwan | 1 | Not yet recruiting | Aug 2027 | 25 |
| NCT06745583Lymphoma, Follicular · Taiwan | 2 | Completed | Mar 6, 2026 | 7 |
| NCT04238364Healthy Volunteers · United States | 1 | Completed | Dec 16, 2021 | 58 |
How it is read
Names in the registry
- “EI-1071”, 2 entries
- “EI-1071 tablet, oral”, 1 entry
Conditions, from the studies’ own filings
- Lymphoma, Follicular, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.